JUVENESCENCE
16.1.2023 10:01:37 CET | Business Wire | Press release
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Upgrades LingGuang to 2.0, Turning Its AI Assistant into a Proactive Personal Agent27.10.2026 09:00:00 CET | Press release
Ant Group today announced the launch of LingGuang 2.0, an upgrade that transforms its multimodal AI assistant into a proactive personal agent capable of identifying user needs and managing tasks over time. Moving beyond passive, single-turn interactions, LingGuang 2.0 shifts AI assistance from responding to commands toward continuously identifying needs, following up on tasks, and coordinating everyday affairs on behalf of users. Unlike conventional conversational AI and task-oriented agents, LingGuang 2.0 moves the starting point of AI assistance earlier in the user’s workflow. Instead of waiting for users to issue a command, LingGuang can, with explicit user authorization, draw on connected information and services to spot potential needs, initiate analysis and follow-ups, and alert users when their attention is required. In this way, it evolves from a reactive tool into a personal agent that continuously manages tasks on the user’s behalf. This shift is powered by comprehensive upgr
Unframe Removes Another Barrier Between AI Capabilities and Adoption27.10.2026 09:00:00 CET | Press release
Available through AWS, Google Cloud and Microsoft marketplaces Unframe, the Applied AI Lab, announced its availability on all three leading cloud marketplaces: AWS Marketplace, Google Cloud Marketplace and Microsoft Marketplace. For enterprises, cloud marketplaces have become the preferred channel for discovering and procuring software. AWS, Google Cloud and Microsoft together serve the vast majority of enterprise cloud infrastructure worldwide. Their marketplaces represent a growing share of how organizations purchase technology by consolidating vendor relationships, simplifying contracting and allowing companies to apply existing cloud spend toward new solutions. Being listed across all three is now a key expectation for enterprise-grade software vendors. “Enterprises shouldn’t have to choose between moving quickly on AI and working within the procurement and cloud frameworks they already have,” said Jacquelyn Goldberg, Global VP of Revenue at Unframe. “As an applied AI lab, our job
Institutional Investors and Wealth Advisors Remain Bullish on Private Markets, With a Sharpened Focus on Liquidity: New Report From BBH Investor Services27.10.2026 09:00:00 CET | Press release
84% of investors* plan to increase their private market investments within the next two yearsPrivate equity and private credit rank highest in asset class strategies for growth66% prefer to deploy capital for four to six years, underscoring preference for greater liquidity and access to capital Private markets are growing in importance to investors’ overall portfolios, according to new research from Brown Brothers Harriman (BBH) Investor Services today. In BBH’s second annual Private Markets Investor Survey, over a quarter of investors say more than 30% of their investments will be allocated to private markets strategies in the next five years. Most investors (84%) plan to increase their private markets investments within the next two years, with private equity ranking as the top target for new investment (54%), up 16 points from last year, followed by private credit (44%), up 20 points year-over-year. The survey captures the views of 500 institutional investors and wealth advisors in
SES and CANAL+ Strengthen Strategic Partnership Through 204027.10.2026 08:50:00 CET | Press release
SES and CANAL+, the global media and entertainment group, have extended their strategic partnership through 2040 with a multi-year agreement covering capacity across Europe, Africa and the Caribbean. Under the renewed agreement, CANAL+ will leverage SES’s satellite infrastructure across several orbital positions to deliver premium video and pay TV services to a global subscriber base that now exceeds 40 million viewers across 70 countries. "SES has been a trusted partner for more than 30 years, helping us deliver premium content to millions of viewers across Europe and Africa. This new agreement supports our long-term growth and provides the flexibility and reliability required as we continue to expand our international footprint and serve an increasingly diverse subscriber base," said Stéphane Baumier, Chief Technology Officer of CANAL+. "CANAL+ is one of SES's most valued and longest-standing customers. This agreement demonstrates the enduring importance of satellite in reliably deli
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom